Richard Pzena’s Jazz Pharmaceuticals JAZZ Stock Holding History

Richard Pzena’s Portfolio JAZZ Stock Details JAZZ Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q4	–	Sell	-1,562	Closed	-$203K	–	178
2021 Q3	$203K	Buy	1,562 +16	+1%	+$2.42K	﹤0.01%	165
2021 Q2	$275K	Buy	+1,546	New	+$268K	﹤0.01%	162
2020 Q3	–	Sell	-4,897	Closed	-$540K	–	170
2020 Q2	$540K	Sell	4,897 -1,201	-20%	-$133K	﹤0.01%	166
2020 Q1	$608K	Buy	+6,098	New	+$788K	﹤0.01%	156

Other funds holding JAZZ

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

LSV Asset Management Chicago, Illinois $55.1B AUM 45.38% 1-Year Est. Return

Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

PCM

Polaris Capital Management Boston, Massachusetts $1.06B AUM 40.82% 1-Year Est. Return

Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

Richard Pzena's JAZZ Position: Q4 2021 in Review

Richard Pzena sold out of Jazz Pharmaceuticals (JAZZ) in Q4 2021, closing a stake of 1,562 shares — an estimated $203K sold.

Richard Pzena first reported a position in JAZZ in Q1 2020 and held it in 4 quarters. The position peaked at $608K in Q1 2020. 455 funds tracked by Wall St. Rank hold JAZZ as of Q4 2021.

Richard Pzena reported no remaining Jazz Pharmaceuticals position as of Q4 2021 after selling out during the quarter.
Richard Pzena sold 1,562 Jazz Pharmaceuticals shares in Q4 2021, an estimated $203K.
Richard Pzena first reported a position in Jazz Pharmaceuticals in Q1 2020 and held it in 4 quarters.
Richard Pzena's Jazz Pharmaceuticals position peaked at $608K in Q1 2020.
455 funds tracked by Wall St. Rank held Jazz Pharmaceuticals as of Q4 2021.

Based on Pzena Investment Management's 13F filing for Q4 2021, filed 4 Feb 2022.